Mutation of KRAS in colorectal adenocarcinoma in Greenland
- PMID: 35655437
- DOI: 10.1111/apm.13254
Mutation of KRAS in colorectal adenocarcinoma in Greenland
Abstract
KRAS mutation is one of the most frequent driver mutations in colorectal cancer (CRC) and is also a prognostic biomarker. The aim of the present study was to determine the frequency of KRAS mutations over time in the Greenlandic population diagnosed with CRC. In total, 578 patients with the diagnosis of adenocarcinoma between 1988 and 2017 were identified. The status of KRAS and the mutational subtypes of KRAS mutations were determined in 102 representative samples by the Idylla™ platform in the time periods 1988-1990, 2002-2004, and 2015-2017. The results showed that the frequency of the KRAS mutations increased significantly, from 27% in 1988-1990 to 43% in 2015-2017 (p < 0.001). Furthermore, the most frequent subtypes of KRAS mutations in Greenland were G12D (c.35G > A) with 14%, G12V (c.35G > T) with 7%, and G13D (c.38G > A) with 6%. In conclusion, this study showed that the frequency of KRAS mutations in CRC has been increasing in recent decades in the specific population of Greenland. The results of this study may be used in initiatives related to targeted therapy of CRC in specific ethnicities and in investigations focusing on the environmental factors of cancer-related somatic mutations.
Keywords: Colorectal cancer; KRAS mutation; greenland; inuit; population genetics.
© 2022 APMIS. Published by John Wiley & Sons Ltd.
Similar articles
-
[The frequency and spectrum of KRAS mutations in metastatic colorectal cancer].Vopr Onkol. 2013;59(6):751-5. Vopr Onkol. 2013. PMID: 24624786 Russian.
-
Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.PLoS One. 2013;8(2):e55793. doi: 10.1371/journal.pone.0055793. Epub 2013 Feb 20. PLoS One. 2013. PMID: 23437064 Free PMC article.
-
[Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].Zhonghua Bing Li Xue Za Zhi. 2012 Oct;41(10):667-70. doi: 10.3760/cma.j.issn.0529-5807.2012.10.005. Zhonghua Bing Li Xue Za Zhi. 2012. PMID: 23302307 Chinese.
-
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21. Genet Med. 2013. PMID: 23429431
-
Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review.Cancer Invest. 2012 Dec;30(10):741-7. doi: 10.3109/07357907.2012.732159. Epub 2012 Oct 17. Cancer Invest. 2012. PMID: 23075074 Review.
Cited by
-
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.Int J Mol Sci. 2023 Jul 27;24(15):12030. doi: 10.3390/ijms241512030. Int J Mol Sci. 2023. PMID: 37569406 Free PMC article. Review.
References
-
- Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356-87.
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
-
- Grady WM, Markowitz SD. The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig Dis Sci. 2015;60(3):762-72.
-
- Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669-85.
-
- Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363-85.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous